Masoud Azodi MD

Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., Wright State University (1992)
  • Residency, Aultman Hospital/Neoucom
  • Fellowship, Yale University School of Medicine

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Pre-malignant and malignant gynecologic disorders involving the vulva, cervix, vagina, uterus, ovaries, and placenta, with emphasis on minimally invasive approaches for gynecologic cancer, including laparoscopic staging, radical vaginal surgeries, and radical tracheolectomy for treatment of cervical cancer with preservation of childbearing capacity; Robotic surgery; Chemotherapy for all gynecologic cancers


Cancers Treated

Cervix, Ovary, Uterus, Vagina & Vulva


Board Certifications

  • Gynecologic Oncology, Board Certified (2002)
  • Obstetrics & Gynecology, Board Certified (2000)

Clinical Trials

ConditionsStudy Title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors

Edit Profile